Description

PIRFEHEAL 200 MG

Indications

PIRFEHEAL 200 MG is primarily indicated for the treatment of various inflammatory conditions, including rheumatoid arthritis and osteoarthritis. It is also utilized in managing acute pain and conditions characterized by excessive inflammation. The medication serves as an adjunct therapy in chronic pain management, providing relief and improving the quality of life for patients suffering from debilitating conditions.

Mechanism of Action

PIRFEHEAL contains the active ingredient pirfenidone, which is known for its anti-inflammatory and antifibrotic properties. The mechanism of action involves the inhibition of several pro-inflammatory cytokines and growth factors that contribute to fibrosis and inflammation. By modulating these pathways, PIRFEHEAL helps reduce the inflammatory response and slows the progression of fibrotic diseases, particularly in the lungs and connective tissues.

Pharmacological Properties

PIRFEHEAL exhibits a unique pharmacological profile. It is classified as a pyridine derivative and is known for its ability to interfere with the synthesis of collagen and other extracellular matrix components. This action is particularly beneficial in conditions where fibrosis is a major concern. The bioavailability of pirfenidone is approximately 60%, and it is metabolized primarily in the liver, with a half-life of about 2 to 4 hours. The drug is excreted mainly through the urine, with a small percentage eliminated in feces.

Contraindications

PIRFEHEAL 200 MG is contraindicated in patients with a known hypersensitivity to pirfenidone or any of the excipients in the formulation. Additionally, it should not be used in individuals with severe liver impairment or active liver disease. Caution is advised in patients with a history of gastrointestinal disorders, particularly those prone to ulcers or bleeding.

Side Effects

Common side effects associated with PIRFEHEAL include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Other reported side effects may include fatigue, rash, and liver enzyme elevations. Serious adverse effects, although rare, can include liver toxicity and hypersensitivity reactions. Patients should be monitored regularly for liver function tests during treatment to detect any potential hepatotoxicity early.

Dosage and Administration

The recommended dosage of PIRFEHEAL 200 MG is typically 600 mg per day, administered in three divided doses of 200 mg each. It is advisable to take the medication with food to enhance absorption and minimize gastrointestinal side effects. Dosage adjustments may be necessary for patients with hepatic impairment or those experiencing significant side effects. It is crucial for patients to follow their healthcare provider’s instructions regarding dosage and administration to ensure optimal therapeutic outcomes.

Interactions

PIRFEHEAL may interact with several medications, which can alter its effectiveness or increase the risk of adverse effects. Notably, drugs that induce or inhibit liver enzymes, particularly CYP1A2, can affect the metabolism of pirfenidone. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking. Special caution is advised when co-administering anticoagulants, as there may be an increased risk of bleeding.

Precautions

Before initiating treatment with PIRFEHEAL, a thorough medical history and assessment should be conducted. Patients with a history of liver disease, gastrointestinal disorders, or those who are pregnant or breastfeeding should exercise caution. Regular monitoring of liver function tests is recommended throughout the treatment course. Patients should be advised to report any unusual symptoms, such as jaundice, severe abdominal pain, or skin rashes, to their healthcare provider immediately.

Clinical Studies

Clinical studies have demonstrated the efficacy of PIRFEHEAL in reducing the progression of fibrosis in patients with idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions. In a randomized controlled trial, patients receiving pirfenidone showed a significant decrease in the decline of lung function compared to those receiving placebo. Furthermore, the safety profile observed in these studies supports the use of PIRFEHEAL in long-term management of fibrotic diseases, with careful monitoring for liver function and side effects.

Conclusion

PIRFEHEAL 200 MG is an effective therapeutic option for managing inflammatory and fibrotic conditions, particularly in patients with rheumatoid arthritis and idiopathic pulmonary fibrosis. Its unique mechanism of action and pharmacological properties make it a valuable addition to the treatment arsenal for these challenging diseases. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Patients should be well-informed about their treatment plan and monitored regularly to ensure optimal outcomes.